Ashford Capital Management Inc. Trims Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Ashford Capital Management Inc. decreased its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 0.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,889,210 shares of the company’s stock after selling 15,070 shares during the quarter. Cellebrite DI comprises about 4.0% of Ashford Capital Management Inc.’s portfolio, making the stock its 2nd largest holding. Ashford Capital Management Inc.’s holdings in Cellebrite DI were worth $31,814,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the stock. Quarry LP purchased a new stake in shares of Cellebrite DI during the 3rd quarter worth approximately $27,000. Point72 Asia Singapore Pte. Ltd. raised its stake in Cellebrite DI by 59.6% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock valued at $33,000 after purchasing an additional 1,017 shares in the last quarter. Advisors Asset Management Inc. lifted its position in Cellebrite DI by 130.5% during the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after purchasing an additional 1,742 shares during the last quarter. Pathway Financial Advisers LLC increased its holdings in shares of Cellebrite DI by 1,583.8% in the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock worth $74,000 after buying an additional 4,118 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado purchased a new stake in shares of Cellebrite DI during the 2nd quarter valued at about $71,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on CLBT. Lake Street Capital boosted their price objective on Cellebrite DI from $13.50 to $17.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Bank of America raised their price target on Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Craig Hallum boosted their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. TD Cowen lifted their price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Cellebrite DI from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $20.29.

Cellebrite DI Stock Down 6.9 %

CLBT opened at $19.88 on Tuesday. Cellebrite DI Ltd. has a 52 week low of $7.91 and a 52 week high of $21.72. The stock’s fifty day moving average is $18.67 and its two-hundred day moving average is $15.56. The company has a market capitalization of $4.09 billion, a P/E ratio of -12.83, a PEG ratio of 2.91 and a beta of 1.51.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The business had revenue of $106.90 million for the quarter, compared to the consensus estimate of $102.06 million. During the same quarter last year, the firm posted $0.09 EPS. The company’s revenue for the quarter was up 27.0% on a year-over-year basis. Equities analysts anticipate that Cellebrite DI Ltd. will post 0.32 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.